Literature DB >> 24591471

Hepatitis C virus: here comes all-oral treatment.

Mohannad Dugum1, Robert O'Shea.   

Abstract

Treatment for chronic hepatitis C virus (HCV) infection is evolving rapidly. The approval in 2013 of two new direct-acting antivirals-sofosbuvir (a polymerase inhibitor) and simeprevir (a second-generation protease inhibitor)-opens the door for an all-oral regimen, potentially avoiding interferon and its harsh side effects. Other direct-acting antivirals are under development.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24591471     DOI： 10.3949/ccjm.81a.13155

Source DB:  PubMed          Journal:  Cleve Clin J Med        ISSN： 0891-1150            Impact factor:   2.321


  10 in total

1.  Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics.

Authors:  Harel Dahari; Shimon Shteingart; Inna Gafanovich; Scott J Cotler; Massimo D'Amato; Ralf T Pohl; Gali Weiss; Yaakov J Ashkenazi; Thomas Tichler; Eran Goldin; Yoav Lurie
Journal:  Liver Int       Date:  2014-10-10       Impact factor: 5.828

2.  Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy.

Authors:  Umberto Restelli; Alfredo Alberti; Adriano Lazzarin; Marzia Bonfanti; Carmela Nappi; Davide Croce
Journal:  Eur J Health Econ       Date:  2016-12-22

Review 3.  Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.

Authors:  Hussien Ahmed; Abdelrahman Ibrahim Abushouk; Amr Menshawy; Arwa Mohamed; Ahmed Negida; Samah A Loutfy; Mohamed M Abdel-Daim
Journal:  Clin Drug Investig       Date:  2017-11       Impact factor: 2.859

4.  Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy.

Authors:  Laetitia Canini; Swati DebRoy; Zoe Mariño; Jessica M Conway; Gonzalo Crespo; Miquel Navasa; Massimo D'Amato; Peter Ferenci; Scott J Cotler; Xavier Forns; Alan S Perelson; Harel Dahari
Journal:  Antivir Ther       Date:  2014-06-10

Review 5.  Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review.

Authors:  Alan Hoi Lun Yau; Eric M Yoshida
Journal:  Can J Gastroenterol Hepatol       Date:  2014-09

Review 6.  Meta-analysis of the efficacy and safety of sofosbuvir for the treatment of hepatitis C virus infection.

Authors:  Hye Jin Yang; Ju Yeon Ryoo; Bong Kyu Yoo
Journal:  Int J Clin Pharm       Date:  2015-06-06

Review 7.  Sofosbuvir: a review of its use in patients with chronic hepatitis C.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2014-07       Impact factor: 11.431

8.  Responding to the public health consequences of the Ukraine crisis: an opportunity for global health diplomacy.

Authors:  Tim K Mackey; Steffanie A Strathdee
Journal:  J Int AIDS Soc       Date:  2015-03-17       Impact factor: 5.396

9.  A Cost-Utility Analysis of Different Antiviral Medicine Regimens in Patients With Chronic Hepatitis C Virus Genotype 1 Infection.

Authors:  Seyed Moayed Alavian; Shekoufeh Nikfar; Abbas Kebriaeezadeh; Farhad Lotfi; Ehsan Sanati; Mohsen Rezaei Hemami; Khosro Keshavarz
Journal:  Iran Red Crescent Med J       Date:  2016-10-02       Impact factor: 0.611

10.  Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.

Authors:  Jingjing Wu; Peng Huang; Haozhi Fan; Ting Tian; Xueshan Xia; Zuqiang Fu; Yan Wang; Xiangyu Ye; Ming Yue; Yun Zhang
Journal:  Virol J       Date:  2019-01-17       Impact factor: 4.099
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.